Introduction
============

Anal carcinoma is a rare cancer type, with an incidence of 1--2 cases/100 000 per year worldwide \[[@mdx029-B1]\]. Approximately 84% of anal carcinoma is associated with high-risk types of human papilloma virus (HPV), primarily HPV-16 \[2\]. The standard of care for localized disease is chemotherapy with 5-fluorouracil (5-FU) and mitomycin in combination with radiotherapy, which results in a 5-year disease-free survival rate of ∼60% \[[@mdx029-B3]\]. Based on limited data, the standard of care after progression or development of distant metastatic disease is 5-FU and cisplatin, and the 5-year survival rate for these patients is ∼15%; however, if cisplatin-based chemotherapy fails, no other regimens have been shown to be effective \[[@mdx029-B6]\].

Many cancers evade immune surveillance and destruction through upregulation of the immune cell checkpoint molecule programmed death ligand 1 (PD-L1). Interaction between the programmed death 1 (PD-1) receptor, expressed on tumor-infiltrating T cells, and its ligand PD-L1 leads to the functional inactivation of T cells, a mechanism known as adaptive immune resistance \[[@mdx029-B7], [@mdx029-B8]\]. Monoclonal antibodies against PD-1 and PD-L1, including pembrolizumab, nivolumab, and atezolizumab, have demonstrated antitumor activity in a diverse set of tumor types \[[@mdx029-B9]\]. A correlation between pretreatment PD-L1 expression and response to anti-PD-1 therapy has also been reported in multiple tumor types \[[@mdx029-B12]\].

The KEYNOTE-028 study evaluated pembrolizumab monotherapy in 20 different PD-L1-positive advanced or recurrent cancers with significant unmet medical need. Results from the anal carcinoma cohort of KEYNOTE-028 are reported herein.

Methods
=======

Study design and population
---------------------------

KEYNOTE-028 (ClinicalTrials.gov, NCT02054806) is a multicenter, open-label, phase Ib trial in 20 cohorts of patients with PD-L1-positive advanced solid tumors. Patients in the anal carcinoma cohort were enrolled at 12 investigational sites in Europe and the USA.

Eligible patients had histologically or cytologically confirmed locally advanced or metastatic carcinoma of the anal canal, failure of prior standard therapy, and tumor PD-L1 positivity. Other eligibility requirements were age ≥18 years, measurable disease based on Response Evaluation Criteria In Solid Tumors, version 1.1 (RECIST v.1.1), Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate organ function as established by laboratory testing conducted \<10 days before the first pembrolizumab dose. Key exclusion criteria included diagnosis of immunodeficiency or systemic steroid therapy \<7 days before the first pembrolizumab dose, active autoimmune disease, interstitial lung disease, active brain metastases (metastases stable for ≥4 weeks before the first pembrolizumab dose were permitted), and previous therapy with an immune checkpoint inhibitor. The study protocol and all amendments were approved by the institutional review boards or ethics committees of all participating sites. All patients provided written informed consent.

Treatment and assessments
-------------------------

Pembrolizumab was given intravenously at 10 mg/kg once every 2 weeks for up to 2 years or until confirmed disease progression, unacceptable toxicity, or patient/investigator decision. Response was assessed by computed tomography or magnetic resonance imaging every 8 weeks for the first 6 months and every 12 weeks thereafter. Adverse events (AEs) were monitored throughout the study and for 30 days after the end of treatment (90 days for serious AEs) and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. AEs of special interest were defined as events with potentially drug-related immunologic causes.

An archived formalin-fixed, paraffin-embedded tumor sample or a newly obtained biopsy specimen was assessed at a central laboratory for PD-L1 expression at screening with a laboratory-developed prototype immunohistochemistry (IHC) assay (QualTek Molecular Laboratories, Goleta, CA) \[[@mdx029-B15]\] using the 22C3 antibody (Merck & Co., Inc., Kenilworth, NJ). PD-L1 positivity was defined as membrane staining of ≥1% of scorable cells, including both neoplastic cells and contiguous mononuclear inflammatory cells, or the presence of a distinctive interface pattern.

Outcomes
--------

Primary endpoints were safety and overall response rate (ORR). ORR was determined by investigator assessment and defined as the proportion of patients having confirmed complete response (CR) or partial response (PR) per RECIST v1.1 at any time during the study. Secondary endpoints included progression-free survival (PFS), defined as time from enrollment to the first documented instance of disease progression according to RECIST v1.1 or death from any cause, whichever occurred first; overall survival (OS), defined as time from enrollment to death from any cause; and duration of response (DOR), defined as time from the first RECIST v1.1-based response to disease progression in patients who experienced PR or better.

Statistical analysis
--------------------

The binomial exact method was used for power and sample size calculations. A sample size of 22 assessable patients in this cohort was calculated to provide 80% power to demonstrate that the best ORR exceeded 10% at an overall one-sided 8% alpha-level if the true ORR within the cohort was 35%. Efficacy was assessed in patients who received ≥1 dose of pembrolizumab and had measurable disease at baseline according to RECIST v1.1. Safety was assessed in patients who received ≥1 dose of pembrolizumab. The truncated sequential probability test was used for evaluation of ORR. The Kaplan--Meier method was used to estimate PFS, OS, and DOR. The data cutoff date for this report was 1 July 2015.

Results
=======

Baseline patient characteristics
--------------------------------

Of 43 patients screened for PD-L1 expression, 32 (74%) had PD-L1-positive tumors as assessed with the prototype IHC assay. Four of these patients did not meet eligibility criteria, three were excluded after the enrollment limit was reached, and the other 25 were enrolled between April and September 2014. Median age was 63 years (range 46--82 years), 23 patients (92%) were women, and the majority (96%) had squamous cell carcinoma (SCC) (Table [1](#mdx029-T1){ref-type="table"}). One patient with non-SCC histology (perineal epidermoid carcinoma) was enrolled as a protocol violation. Most patients were pretreated, with 13 (52%) having received ≥2 prior treatments for advanced disease. Although three (12%) patients did not receive prior treatment of advanced disease, they experienced disease progression shortly after receiving adjuvant and/or (neo)adjuvant treatment. Table 1Patient baseline characteristicsCharacteristic*N* = 25Median age, years  (range)63  (46--82)Sex   Male2  (8)   Female23  (92)Race   White19  (76)   Black or African American1  (4)   Not specified5  (20)ECOG performance status   05  (20)   120  (80)Histology at baseline   SCC24  (96)   Perineal epidermoid carcinoma^a^1  (4)Adjuvant or neoadjuvant systemic therapy6  (24)Prior radiation18  (72)Prior lines of therapy for advanced disease   0[^b^](#tblfn3){ref-type="table-fn"}3  (12)   17  (28)   26  (24)  ≥37  (28)   Unknown2  (8)Prior therapies for advanced disease[^c^](#tblfn4){ref-type="table-fn"}   5-FU + mitomycin15  (60)   5-FU ± platinum ± other12  (48)   Gemcitabine + platinum ± other4  (16)   Chk-1 inhibitor2  (8)   Etirinotecan pegol2  (8)   Other10  (40)[^1][^2][^3][^4][^5]

Safety
------

As of the data cutoff date, median follow-up duration was 10.6 months (range 0.3--15.0 months) and median duration of therapy was 92 days (range 1--449 days). Sixteen patients (64%) experienced treatment-related AEs (Table [2](#mdx029-T2){ref-type="table"}), most commonly diarrhea, fatigue (*n* = 4 each; 16%), and nausea (*n* = 3; 12%). There were four grade 3 treatment-related AEs, including increased blood thyroid-stimulating hormone (TSH) level and general physical health deterioration (*n* = 1 each), and colitis and diarrhea in the same patient. No grade 4 or higher treatment-related AEs were seen. Treatment-related AEs of special interest occurred in three patients (12%): grade 2 hypothyroidism in two patients and grade 3 colitis in one patient. One additional patient experienced grade 2 hypothyroidism not considered by the investigator to be related to treatment and grade 3 treatment-related increased TSH, which was not included as a term in the analysis of AEs of special interest. Table 2Treatment-related adverse eventsAny-grade adverse events occurring in ≥ 2 patients, *n* (%)*N* = 25 Diarrhea4 (16) Fatigue4 (16) Nausea3 (12) Dry mouth2 (8) Hypersensitivity2 (8) Hypothyroidism2 (8) Night sweats2 (8) Stomatitis2 (8) Thrombocytopenia2 (8) Vomiting2 (8)**Grade 3- -4 adverse events occurring in ≥ 1 patient, *n* (%)** Colitis (grade 3)[^a^](#tblfn6){ref-type="table-fn"}1 (4) Diarrhea (grade 3)[^a^](#tblfn6){ref-type="table-fn"}1 (4) General physical health deterioration (grade 3)1 (4) Increased blood thyroid stimulating hormone (grade 3)1 (4)[^6]

Of 25 enrolled patients, one patient discontinued therapy because of toxicity before the first postbaseline response evaluation (grade 5 intestinal perforation unrelated to pembrolizumab treatment). There were no treatment-related study discontinuations or deaths as of the data cutoff date.

Clinical activity
-----------------

By investigator review, ORR was 17% \[95% confidence interval (CI), 5.0%--37%\] among the 24 patients with SCC histology, and all four patients had confirmed PR (Table [3](#mdx029-T3){ref-type="table"}). Ten patients (42%) had confirmed stable disease (SD) with a median duration of 3.6 months (range 1.8+ to 11+ months). The disease control rate was 58% (14 of 24 patients). The one patient with non-SCC histology (perineal epidermoid carcinoma) had confirmed SD at 9 weeks and unconfirmed PR as of the data cutoff date and was subsequently lost to follow-up. All five responders, regardless of histology, had received prior therapy for advanced disease. Table 3Best overall response in patients with SCC histology (*N* = 24)Best response[^a^](#tblfn7){ref-type="table-fn"}*n*%95% CIComplete response000--14Partial response4175--37Stable disease104222--63Progressive disease93819--59Not assessed[^b^](#tblfn8){ref-type="table-fn"}140--21[^7][^8][^9]

Overall, nine (38%) of 24 assessable patients had a decrease from baseline in the size of their target lesions (Figure [1](#mdx029-F1){ref-type="fig"}A), which was maintained over several assessments (Figure [1](#mdx029-F1){ref-type="fig"}B). Among the five patients with a response, regardless of histology, median time to response was 3.6 months (range 1.6--4.8 months), and median DOR was not reached (range \<0.1+ to 9.2+ months). At the time of analysis, two of the four responses in patients with SCC histology were ongoing (Figure [1](#mdx029-F1){ref-type="fig"}C) and were sustained for longer than 9 months (see [supplementary materials](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online, for additional details on these two patients). Two patients with SD also remained on treatment as of the data cutoff date. Figure 1.(A) Maximum change from baseline in tumor size. Includes patients with ≥1 postbaseline tumor assessment (*n* = 24). Responders were defined as patients having confirmed complete response or partial response per RECIST v1.1 by investigator review. (B) Longitudinal change from baseline in tumor size. Includes patients with ≥1 postbaseline tumor assessment (*n* = 24). Responders were defined as patients having confirmed complete response or partial response per RECIST v1.1 by investigator review. (C) Treatment exposure and response duration. The length of each bar represents the time to the last radiographic assessment. Both confirmed and unconfirmed responses per RECIST v1.1 by investigator review are shown.

Median PFS was 3.0 months (95% CI 1.7--7.3 months), and 6- and 12-month PFS rates were 31.6% and 19.7%, respectively ([supplementary Figure S1A](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). Median OS was 9.3 months (95% CI, 5.9 months to not available), and the 6- and 12-month OS rates were 64.5% and 47.6%, respectively ([supplementary Figure S1B](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online).

Discussion
==========

Because PD-L1 expression is associated with higher antitumor activity of PD-1 blockade in other tumor types \[[@mdx029-B12]\], PD-L1 positivity was used as a selection criterion in this study to potentially enrich for patients most likely to respond to pembrolizumab. In this population of mostly pretreated patients with PD-L1-positive advanced anal carcinoma, pembrolizumab demonstrated manageable safety and encouraging antitumor activity, with an ORR of 17% in those patients with SCC histology (4 of 24 patients). To our knowledge, this study represents the first published manuscript describing immune checkpoint blockade in patients with previously treated advanced anal carcinoma.

PD-L1 positivity, which had not been previously defined in anal cancer, was found to be high (74% of screened patients) in this study. The high rate of PD-L1 expression in anal cancer may not be surprising given the immune responses against the HPV E7 oncoprotein identified previously in this tumor type \[[@mdx029-B16]\]. High frequencies of tumor-infiltrating lymphocytes and inflammatory responses have been identified in virally driven cancers and have been linked with upregulation of PD-L1 in HPV-associated head and neck cancer \[[@mdx029-B17]\]. This upregulation of PD-L1 is mediated by interferon-γ secreted by T cells and has been termed 'adaptive immune resistance' \[[@mdx029-B8], [@mdx029-B20]\]. HPV status was not collected in this study and was only available for three of the enrolled patients (two responders and one non-responder), all of whom were HPV positive. The number of patients in this study with known HPV status was too small to determine an association with pembrolizumab activity.

Similar to the results of other immune checkpoint inhibitors in various tumor types \[[@mdx029-B11]\], only a subset of patients with PD-L1-positive tumors in this study experienced clinical benefit, suggesting that other biomarkers should be explored for the ability to predict antitumor activity of pembrolizumab. Immune gene signatures were shown to correlate with response to PD-1 blockade in several other solid tumor types \[[@mdx029-B21]\], and an association between tumor infiltration of CD8+ and CD3+ T cells with response to PD-1 inhibition was reported with another anti-PD-1 antibody, nivolumab, in patients with SCC anal carcinoma \[[@mdx029-B24]\]. Mutational load has been reported to correlate with response to immune checkpoint blockade in other cancers including melanoma, non-small cell lung cancer, and colorectal cancer, and may be relevant in advanced anal carcinoma as well \[[@mdx029-B25]\]. Although the mutational rate of anal cancer has not been assessed comprehensively, it has been reported to be in the intermediate range, along with other HPV-associated cancers such as head and neck and cervical cancer \[[@mdx029-B29]\].

In conclusion, pembrolizumab demonstrated manageable safety and encouraging antitumor activity in patients with PD-L1-positive advanced SCC anal carcinoma. Further evaluation of PD-1 blockade, alone or in combination with a partnering agent, in this patient population and of potential biomarkers is warranted.
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Key Messages
============

No regimens are effective for advanced anal carcinoma after progression on cisplatin-based chemotherapy.The KEYNOTE-028 study demonstrated that the anti-PD-1 antibody pembrolizumab has manageable toxicity and encouraging antitumor activity in mostly pretreated patients with PD-L1-positive advanced anal carcinoma.These results support further study of pembrolizumab in this patient population.

[^1]: Data are presented as *n*  (%) unless indicated otherwise.

[^2]: Protocol violation.

[^3]: Although these three patients did not receive prior treatment for advanced disease, they had disease progression shortly after receiving adjuvant and/or  (neo)adjuvant treatment.

[^4]: Patients could have received \>1 prior therapy.

[^5]: 5-FU, 5-fluorouracil; Chk-1, checkpoint kinase 1; ECOG, Eastern Cooperative Oncology Group; SCC, squamous cell carcinoma.

[^6]: Occurred in the same patient.

[^7]: All responses are confirmed.

[^8]: Patient discontinued therapy because of toxicity before the first post-baseline response assessment.

[^9]: CI, confidence interval; SCC, squamous cell carcinoma.
